Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review.
Cancer
Clinical pharmacist
Clinical pharmacy
Injectable anticancer drugs
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
05
11
2022
accepted:
01
02
2023
medline:
31
7
2023
pubmed:
1
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
Clinical pharmacy can reduce drug-related iatrogenesis by improving the management of adverse effects of drugs, limiting drug-drug interactions, and improving patient adherence. Given the vulnerability of cancer patients and the toxicity of injectable anticancer drugs, clinical pharmacy service (CPS) could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on clinical pharmacy's impact on patients treated with intravenous anticancer drugs. A comprehensive search was performed in the PubMed/Medline database from January 2000 to December 2021, associating the keywords: clinical pharmacy, pharmaceutical care, pharmacist, oncology, and chemotherapy. To be eligible for inclusion, studies have to report clinical pharmaceutical services for patients treated with intravenous chemotherapy with a clinical and/or economic impact. Forty-one studies met the selection criteria. Various CPS were reported: medication reconciliation, medication review, and pharmaceutical interview with patient. There was a lack of randomized study (n = 3; 7.3%). In one randomized controlled trial, pharmaceutical intervention significantly improved quality of life of patients receiving pharmaceutical care during injectable anticancer drugs courses. Economical results appear to show positive impact of clinical pharmacy with cost savings reported from 3112.87$ to 249 844€. Although most studies were non-comparative, they highlighted that clinical pharmacy tend to limit chemotherapy side effects and drug-related problems, improve quality of life and satisfaction of patients and healthcare professional, and a positive economic impact. Clinical pharmacy can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.
Identifiants
pubmed: 36853384
doi: 10.1007/s00432-023-04630-4
pii: 10.1007/s00432-023-04630-4
doi:
Substances chimiques
Antineoplastic Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7905-7924Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ahmed A, Saqlain M, Tanveer M, Blebil AQ, Dujaili JA, Hasan SS (2021) The impact of clinical pharmacist services on patient health outcomes in Pakistan: a systematic review. BMC Health Serv Res 21:859
pubmed: 34425816
pmcid: 8381566
Ali K, Al-Quteimat O, Naseem R, Malhi SM, Wajdi M, Jahan N et al (2021) Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance. J Oncol Pharm Pract 27(4):815–820
pubmed: 32633660
Allison J, Fisher J, Souter C, Bennie M (2019) What patient assessment skills are required by pharmacists prescribing systemic anti-cancer therapy? A consensus study. J Oncol Pharm Pract 25(8):1933–1944
pubmed: 31042136
Al-Taie A, Izzettin FV, Sancar M et al (2020) Impact of clinical pharmacy recommendations and patient counselling program among patients with diabetes and cancer in outpatient oncology setting. Eur J Cancer Care 29:e13261
American College of Clinical Pharmacy (2008) The definition of clinical pharmacy. Pharmacotherapy 28(6):816–817
Ashjian E, Salamin LB, Eschenburg K, Kraft S, Mackler E (2015) Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. J Am Pharm Assoc 55(5):540–545
Barral M, Martin J, Carre E, Janoly-Dumenil A, Ranchon F, Parat S, Rioufol C et al (2021) 5P Study Group. How a patient personalised clinical pharmacy programme can secure therapeutic care in an orthogeriatric care pathway (5P Project). Clin Interv Aging 16:1857–1867
pubmed: 34707352
pmcid: 8544550
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198
pubmed: 28586821
pmcid: 5817466
Bates JS, Auten J, Sketch MR, Patel T, Clark SM, Morgan KP et al (2019) Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation. J Oncol Pharm Pract 25(4):896–902
pubmed: 30808278
Baudouin A, Herledan C, Poletto N, Guillemin MD, Maison O, Garreau R et al (2021) Economic impact of clinical pharmaceutical activities in hospital wards: a systematic review. Res Social Adm Pharm 17(3):497–505
pubmed: 32819880
Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E et al (2016) Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer 122(4):598–610
pubmed: 26599199
Boşnak AS, Birand N, Diker Ö, Abdi A, Başgut B (2019) The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy. J Oncol Pharm Pract 25(6):1312–1320
pubmed: 29984626
Caracuel F, Baños Ú, Herrera MD, Ramírez G, Muñoz N (2014) Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm 36(2):287–290
pubmed: 24477720
Chan A, Shih V, Chiang J, Chew L, Tay K, Quek R et al (2013) Clinical pharmacy services and research for lymphoma patients at a cancer center. J Oncol Pharm Pract 19(1):24–30
pubmed: 22706787
Chew C, Chiang J, Yeoh TT (2015) Impact of outpatient interventions made at an ambulatory cancer centre oncology pharmacy in Singapore. J Oncol Pharm Pract 21(2):93–101
pubmed: 24477774
Collomb B, Dubromel A, Caffin AG, Herledan C, Larbre V, Baudouin A et al (2022) Assessment of patient reported outcomes (PROs) in outpatients taking oral anticancer drugs included in the real-life oncoral program. Cancers (basel) 14(3):660
pubmed: 35158928
Crespo A, Tyszka M (2017) Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit. J Oncol Pharm Pract 23(4):243–248
pubmed: 26911478
da Silva BA, Krishnamurthy M (2016) The alarming reality of medication error: a patient case and review of Pennsylvania and National data. J Community Hosp Intern Med Perspect 6(4):31758
pubmed: 27609720
Damery S, Gratus C, Grieve R, Warmington S, Jones J, Routledge P, Greenfield S, Dowswell G, Sherriff J, Wilson S (2011) The use of herbal medicines by people with cancer: A cross-sectional survey. Br J Cancer 104:927–933
pubmed: 21364591
pmcid: 3065283
Daupin J, Perrin G, Lhermitte-Pastor C, Loustalot MC, Pernot S, Savoldelli V et al (2019) Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: a cross-sectional study. J Oncol Pharm Pract 25(5):1195–1203
pubmed: 30691354
de Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C et al (2020) Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department. J Oncol Pharm Pract 26(5):1172–1179
pubmed: 32299314
Delpeuch A, Leveque D, Gourieux B, Herbrecht R (2015) Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res 35(1):457–460
pubmed: 25550587
Döhler N, Krolop L, Ringsdorf S, Meier K, Ko YD, Kuhn W et al (2011) Task allocation in cancer medication management - integrating the pharmacist. Patient Educ Couns 83(3):367–374
pubmed: 21482061
Dreischulte T, van den Bemt B, Steurbaut S (2022) European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: a position paper. Int J Clin Pharm 44(4):837–842
pubmed: 35668277
pmcid: 9393137
Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J et al (2014) Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract 27(1):46–52
pubmed: 24065784
Edwards Z, Ziegler L, Craigs C, Blenkinsopp A, Bennett MI (2019) Pharmacist educational interventions for cancer pain management: a systematic review and meta-analysis. Int J Pharm Pract 27(4):336–345
pubmed: 30707465
Engdal S, Steinsbekk A, Klepp O, Nilsen OG (2008) Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 16(7):763–769
pubmed: 18196289
Farias TF, Aguiar KD, Rotta I, Belletti KM, Carlotto J (2016) Implementing a clinical pharmacy service in hematology. Einstein (sao Paulo) 14(3):384–390
pubmed: 27759828
Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A et al (2005) Medication safety in the ambulatory chemotherapy setting. Cancer 104(11):2477–2483
pubmed: 16245353
Gerber A, Da Silva LA, Szüts N, Simon M, Ribordy-Baudat V, Ebneter A et al (2020) Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. Health Sci Rep 3(2):e160
pubmed: 32405540
pmcid: 7217322
Granados J, Salazar-Ospina A, Botero-Aguirre JP, Valencia-Quintero AF, Ortiz N, Amariles P (2020) Effect and associated factors of a clinical pharmacy model in the incidence of medication errors (EACPharModel) in the Hospital Pablo Tobón Uribe: study protocol for a stepped wedge randomized controlled trial (NCT03338725). Trials 21(1):26
pubmed: 31907009
pmcid: 6945697
Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF et al (2018) PCNE definition of medication review: reaching agreement. Int J Clin Pharm 40(5):1199–1208
pubmed: 30073611
Guo Q, Guo H, Song J et al (2020) The role of clinical pharmacist trainees in medication reconciliation process at hospital admission. Int J Clin Pharm 42(2):796–804
pubmed: 32221824
Gurwitz JH, Kapoor A, Garber L et al (2021) Effect of a multifaceted clinical pharmacist intervention on medication safety after hospitalization in persons prescribed high-risk medications: a randomized clinical trial. JAMA Intern Med 181(5):610–618
pubmed: 33646267
pmcid: 7922235
Hamel C, Tortolano L, Bermudez E, Desmaris R, Klein S, Slimano F et al (2018) Computerized pediatric oncology prescriptions review by pharmacist: A descriptive analysis and associated risk factors. Pediatr Blood Cancer 65(4):e26897
Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA et al (2016) Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm 38(5):1124–1132
pubmed: 27365091
Hatoum HT, Hutchinson RA, Witte KW et al (1988) Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 22:252–259
pubmed: 3366065
Haukland EC, von Plessen C, Nieder C, Vonen B (2017) Adverse events in hospitalized cancer patients: a comparison to a general hospital population. Acta Oncol 56(9):1218–1223
pubmed: 28379721
Herledan C, Baudouin A, Larbre V, Gahbiche A, Dufay E, Alquier I et al (2020) Clinical and economic impact of medication reconciliation in cancer patients: a systematic review. Support Care Cancer 28(8):3557–3569
pubmed: 32189099
Hibbard JH, Stockard J, Mahoney ER, Tusler M (2004) Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 39(4 Pt 1):1005–1026
pubmed: 15230939
pmcid: 1361049
Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H et al (2020) Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer 28(12):5943–5952
pubmed: 32281034
pmcid: 7686000
Holle LM, Harris CS, Chan A, Fahrenbruch RJ, Labdi BA, Mohs JE et al (2017) Pharmacists’ roles in oncology pharmacy services: Results of a global survey. J Oncol Pharm Pract 23(3):185–194
pubmed: 26854267
Homan MJ, Reid JH, Nachar VR, Benitez LL, Brown AM, Kraft S et al (2021) Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. Support Care Cancer 29(11):6505–6510
pubmed: 33905012
Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther 11:187–203
pubmed: 22019489
Imamura M, Ogawa D, Takatori T, Yamaguchi M, Takata T, Hada T et al (2017) A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs. Biol Pharm Bull 40(11):1956–1962
pubmed: 29093344
Ismail M, Khan S, Khan F, Noor S, Sajid H, Yar S et al (2020) Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer 20(1):335
pubmed: 32307008
pmcid: 7168989
Jacobson JO, Polovich M, McNiff KK, Lefebvre KB, Cummings C, Galioto M et al (2009) American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 27(32):5469–5475
pubmed: 19786650
Jarfaut A, Nivoix Y, Vigouroux D, Kehrli P, Gaudias J, Kempf JF et al (2014) Clinical pharmacy and surgery: Review. Ann Pharm Fr 72(3):152–163
pubmed: 24780831
Kabel AM, Bakr MM, Alshanbari AM, Alwagdani SM, Altalhi HA, Alzaidi SH et al (2020) Perceptions and attitudes towards clinical pharmacy services and their impact on the management of cancer in Taif, Saudi Arabia. Asian Pac J Cancer Prev 21(2):531–538
pubmed: 32102535
pmcid: 7332119
Kaya M, Nakamura K, Nagamine M, Suyama Y, Nakajo M, Uchida R et al (2021) A retrospective study comparing interventions by oncology and non-oncology pharmacists in outpatient chemotherapy. Cancer Rep 4(4):e1371
Knez L, Laaksonen R, Duggan C (2010) Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol 44(4):249–256
pubmed: 22933924
pmcid: 3423705
Korayem GB, Badreldin HA, Eljaaly K, Aldemerdash A, Al-Suhaibani LK, Joharji H et al (2021) Clinical pharmacy definition, required education, training and practice in Saudi Arabia: A position statement by the Saudi society of clinical pharmacy. Saudi Pharm J 29(11):1343–1347
pubmed: 34819795
pmcid: 8596147
Kucuk E, Bayraktar-Ekincioglu A, Erman M, Kilickap S (2020) Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. J Oncol Pharm Pract 26(3):595–602
pubmed: 31342849
Lau KM, Saunders IM, Sacco AG, Barnachea LC (2020) Evaluation of pharmacist interventions in a head and neck medical oncology clinic. J Oncol Pharm Pract 26(6):1390–1396
pubmed: 31937188
Laurent V, Saillard J, Thierry M, Lepelletier A, Fronteau C, Huon JF (2021) Anticancer agents and herbal medicine: Interactions that are often unrecognized. J Oncol Pharm Pract 27(2):322–328
pubmed: 32356688
Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D et al (2015) Study impacto: Descriptive analyzis of pharmacist’s clinical practice in onco-hematology. Ann Pharm Fr 73(3):223–228
pubmed: 25934530
Le S, Chang B, Pham A, Chan A (2021) Impact of pharmacist-managed immune checkpoint inhibitor toxicities. J Oncol Pharm Pract 27(3):596–600
pubmed: 32507100
Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R et al (2021) Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer 127(11):1827–1835
pubmed: 33524183
Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W et al (2012) Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 20(11):2669–2677
pubmed: 22298194
pmcid: 3461211
Lihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi Y et al (2012) Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract 18(4):753–760
Lipitz-Snyderman A, Pfister D, Classen D, Atoria CL, Killen A, Epstein AS et al (2017) Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer 123(23):4728–4736
pubmed: 28817180
Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus FV (2014) Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm 36(6):1251–1259
pubmed: 25326824
Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S (2019) A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. J Oncol Pharm Pract 25(1):130–139
pubmed: 29938594
Martínez-Bautista MJ, Mangues-Bafalluy I, Cajaraville-Ordoñana G, Carreras-Soler MJ, Clopés-Estela A, Moreno-Martínez E (2019) Survey of oncohematological pharmaceutical care situation in Spain. Farma Hosp 43(6):194–201
McKee M, Frei BL, Garcia A, Fike D, Soefje SA (2011) Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract 17(4):387–394
pubmed: 21239453
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
pubmed: 19621072
pmcid: 2707599
Morimoto Y, Takei H, Tachibana K, Nakazato Y, Tanaka R, Nagashima Y et al (2018) Role of pharmacists in completion of adjuvant cisplatin-vinorelbine chemotherapy in japanese patients with non-small cell lung cancer. Yakugaku Zasshi 138(3):437–442
pubmed: 29503435
Moukafih B, Abahssain H, Mrabti H, Errihani H, Rahali Y, Taoufik J et al (2021) Impact of clinical pharmacy services in a hematology/oncology ward in Morocco. J Oncol Pharm Pract 27(2):305–311
pubmed: 32326873
Muñoz-Pichuante D, Villa-Zapata L (2020) Benefit of incorporating clinical pharmacists in an adult intensive care unit: a cost-saving study. J Clin Pharm Ther 45:1127–1133
pubmed: 32497354
Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS et al (2013) Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs. J Oncol Pharm Pract 19(1):8–17
pubmed: 22623276
Oliveira CS, Silva MP, Miranda ÍK, Calumby RT, de Araújo-Calumby RF (2021) Impact of clinical pharmacy in oncology and hematology centers: a systematic review. J Oncol Pharm Pract 27(3):679–692
pubmed: 33302824
Omar NE, Elazzazy S, Abdallah O, Nashwan AJ, Eltorki Y, Afifi HM et al (2020) Perceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in Qatar. J Oncol Pharm Pract 26(5):1086–1096
pubmed: 31718469
Opsomer MA, Anota A, Noblot-Rossignol M, Bonnetain F, Pernot C, Chretien ML et al (2016) Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies. Ann Pharm Fr 74(6):439–447
pubmed: 27162122
Overhage JM, Lukes A (1999) Practical, reliable, comprehensive method for characterizing pharmacists’ clinical activities. Am J Health Syst Pharm 56(23):2444–2450
pubmed: 10595804
Penm J, Vaillancourt R, Pouliot A (2019) Defining and identifying concepts of medication reconciliation: an international pharmacy perspective. Res Social Adm Pharm 15(6):632–640
pubmed: 30100200
Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C (2017) Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract 13(7):e613–e622
pubmed: 28628392
Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S et al (2011) Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer 11:478
pubmed: 22067636
pmcid: 3262863
Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N et al (2012) Predictors of prescription errors involving anticancer chemotherapy agents. Eur J Cancer 48(8):1192–1199
pubmed: 22285178
Renna CE, Dow EN, Bergsbaken JJ, Leal TA (2019) Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities. J Oncol Pharm Pract 25(4):954–960
pubmed: 30975067
Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99(8):592–600
pubmed: 17440160
Ruder AD, Smith DL, Madsen MT, Kass FH 3rd (2011) Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic? J Oncol Pharm Pract 17(4):425–432
pubmed: 21248174
Sam S, Guérin A, Rieutord A, Belaiche S, Bussières JF (2018) Roles and impacts of the transplant pharmacist: a systematic review. Can J Hosp Pharm 71(5):324–337
pubmed: 30401999
pmcid: 6209508
Schindel TJ, Given LM (2013) The pharmacist as prescriber: a discourse analysis of newspaper media in Canada. Res Social Adm Pharm 9(4):384–395
pubmed: 22835707
Segal EM, Bates J, Fleszar SL, Holle LM, Kennerly-Shah J, Rockey M et al (2019) Demonstrating the value of the oncology pharmacist within the healthcare team. J Oncol Pharm Pract 25(8):1945–1967
pubmed: 31288634
Shah S, Dowell J, Greene S (2006) Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 40(9):1527–1533
pubmed: 16882869
Shrestha S, Shakya D, Palaian S (2020) Clinical pharmacy education and practice in nepal: a glimpse into present challenges and potential solutions. Adv Med Educ Pract 11:541–548
pubmed: 32884392
pmcid: 7439280
Société Française de Pharmacie Clinique. Lexique de Pharmacie Clinique. [Online]. 2018 [consulted 20/12/2021]. Available on: https://sfpc.eu/wp-content/uploads/2019/11/1-s.0.S2211104218302005-mmc1.pdf
Son H, Kim J, Kim C, Ju J, Lee Y, Rhie SJ (2018) Pharmacist-led interdisciplinary medication reconciliation using comprehensive medication review in gynaecological oncology patients: a prospective study. Eur J Hosp Pharm 25(1):21–25
pubmed: 31156980
Stämpfli D, Baumgartner P, Boeni F et al (2019) Translation and validation of a tool to assess the impact of clinical pharmacists’ interventions. Int J Clin Pharm 41:56–64
pubmed: 30478493
Suzuki H, Suzuki S, Kamata H, Sugama Y, Demachi K, Ikegawa K et al (2019) Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J Oncol Pharm Pract 25(7):1558–1563
pubmed: 30180775
Tariq RA, Vashisht R, Sinha A, Scherbak Y (2021) StatPearls [Internet] Treasure Island, FL: StatPearls Publishing. Medication dispensing errors and prevention
Tefera GM, Zeleke AZ, Jima YM, Kebede TM (2020) Drug therapy-related problems and the role of clinical pharmacist in surgery Ward: prospective observational and interventional study. Drug Healthc Patient Saf 12:71–83
pubmed: 32440225
pmcid: 7210033
Tezcan S, İzzettin FV, Sancar M, Turhal NS, Yumuk PF (2018) Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer. Eur J Hosp Pharm 25(e1):e17–e20
pubmed: 31157061
Theuser AK, Hack CC, Fasching PA, Antoniadis S, Grasruck K, Wasner S et al (2021) Patterns and trends of herbal medicine use among patients with gynecologic cancer. Geburtshilfe Frauenheilkd 81(6):699–707
pubmed: 34168382
pmcid: 8216777
Tissot M, Valnet-Rabier M, Stalder T, Limat S, Davani S, Nerich V (2021) Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies 77:291
Van der Linden L, Hias J, Walgraeve K, Flamaing J, Tournoy J, Spriet I (2020) Clinical pharmacy services in older inpatients: an evidence-based review. Drugs Aging 37(3):161–174
pubmed: 31919802
van Leeuwen RW, Swart EL, Boven E et al (2011) Potential drug interactions in cancer therapy: A prevalence study using an advanced screening method. Ann Oncol 22:2334–2341
pubmed: 21343376
van Leeuwen RWF, Jansman FGA, van den Bemt P, de Man F, Piran F, Vincenten I et al (2015) Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 26(5):992–997
pubmed: 25628444
van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA (2004) Drug-related problem classification systems. Ann Pharmacother 38:859–867
pubmed: 15054145
Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG et al (2015) EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther 40(2):196–203
pubmed: 25594148
Vega TG, Sierra-Sánchez JF, Martínez-Bautista MJ, García-Martín F, Suárez-Carrascosa F, Baena-Cañada JM (2016) Medication reconciliation in oncological patients: a randomized clinical trial. J Manag Care Spec Pharm 22(6):734–740
pubmed: 27231800
Vucur C, Wirtz DA, Weinhold L, Zipfel M, Schmid M, Schmidt-Wolf IG et al (2021) Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles. J Oncol Pharm Pract 27(6):1439–1446
pubmed: 33019873
Walsh KE, Dodd KS, Seetharaman K, Roblin DW, Herrinton LJ, Von Worley A et al (2009) Medication errors among adults and children with cancer in the outpatient setting. J Clin Oncol 27(6):891–896
pubmed: 19114695
Wang Y, Wu H, Xu F (2015) Impact of clinical pharmacy services on KAP and QOL in cancer patients: a single-center experience. Biomed Res Int 2015:502431
pubmed: 26697487
pmcid: 4677164
Weingart SN, Zhang L, Sweeney M, Hassett M (2018) Chemotherapy medication errors. Lancet Oncol 19(4):e191–e199
pubmed: 29611527
Xie C, Mu X, Hu Z, Wang W, Huang W, Huang G et al (2020) Impact of pharmaceutical care in the orthopaedic department. J Clin Pharm Ther 45(3):401–407
pubmed: 31800132
Xu P, Hu YY, Yuan HY, Xiang DX, Zhou YG, Cave AJ, Banh HL (2019) the impact of a training program on clinical pharmacists on pharmacy clinical services in a tertiary hospital in Hunan China. J Multidiscip Healthc 12:975–980
pubmed: 31819471
pmcid: 6885557
Zecchini C, Vo TH, Chanoine S, Lepelley M, Laramas M, Lemoigne A, Allenet B, Federspiel I, Bedouch P (2020) BMC Health Serv Res 20(1):113
pubmed: 32050957
pmcid: 7017539
Zhou M, Desborough J, Parkinson A, Douglas K, McDonald D, Boom K (2019) Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences. Int J Pharm Pract 27(6):479–489
pubmed: 31287208